Anavex Life Sciences Advances in Parkinson’s Disease Research
Anavex Life Sciences is making notable strides in the field of neurodegenerative diseases, particularly with its promising results in treating Parkinson’s disease. The biopharmaceutical company recently reported positive outcomes from its 48-week Phase 2 extension study involving the drug ANAVEX®2-73 (blarcamesine). The study, focusing on patients with Parkinson’s disease dementia, successfully achieved both its primary and secondary objectives. The participants […]
